NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹119 Cr | ₹87 Cr | ₹58 Cr | ₹66 Cr | ₹42 Cr |
What is the latest Total Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹119 Cr |
| Mar2024 | ₹87 Cr |
| Mar2023 | ₹58 Cr |
| Mar2022 | ₹66 Cr |
| Mar2021 | ₹42 Cr |
How is Total Current Liabilities of NGL FINECHEM Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹119 Cr | 37.40 | |
| Mar2024 | ₹87 Cr | 48.54 | |
| Mar2023 | ₹58 Cr | -11.21 | |
| Mar2022 | ₹66 Cr | 57.19 | |
| Mar2021 | ₹42 Cr | - | |
Compare Total Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,438.2 Cr | 4% | 32.6% | 129.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,728.0 Cr | -0.8% | 7.4% | 8.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,236.0 Cr | -1.5% | 5.7% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,951.0 Cr | -1.8% | 8.8% | 44.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,765.0 Cr | -1.2% | 9.2% | 14.9% | Stock Analytics | |
| CIPLA | ₹106,033.0 Cr | -2.5% | 0.1% | -7.6% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 4% |
32.6% |
129.3% |
| SENSEX | -3.8% |
-2% |
6.3% |
You may also like the below Video Courses